These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 28636052)

  • 21. Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines.
    Falco GD; Neri LM; Falco MD; Bellan C; Yu Z; Luca AD; Leoncini L; Giordano A
    Oncogene; 2002 Oct; 21(49):7464-70. PubMed ID: 12386808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation.
    Ottis P; Toure M; Cromm PM; Ko E; Gustafson JL; Crews CM
    ACS Chem Biol; 2017 Oct; 12(10):2570-2578. PubMed ID: 28767222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Degradation of CDK9 Potently Disrupts the MYC Transcriptional Network.
    Toure MA; Motoyama K; Xiang Y; Urgiles J; Kabinger F; Koglin AS; Iyer RS; Gagnon K; Kumar A; Ojeda S; Harrison DA; Rees MG; Roth JA; Ott CJ; Schiavoni R; Whittaker CA; Levine SS; White FM; Calo E; Richters A; Koehler AN
    bioRxiv; 2024 May; ():. PubMed ID: 38952800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ensemble-based modeling and rigidity decomposition of allosteric interaction networks and communication pathways in cyclin-dependent kinases: Differentiating kinase clients of the Hsp90-Cdc37 chaperone.
    Stetz G; Tse A; Verkhivker GM
    PLoS One; 2017; 12(11):e0186089. PubMed ID: 29095844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.
    Bellan C; De Falco G; Lazzi S; Micheli P; Vicidomini S; Schürfeld K; Amato T; Palumbo A; Bagella L; Sabattini E; Bartolommei S; Hummel M; Pileri S; Tosi P; Leoncini L; Giordano A
    J Pathol; 2004 Aug; 203(4):946-52. PubMed ID: 15258998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma.
    Zhang Y; Zhou L; Leng Y; Dai Y; Orlowski RZ; Grant S
    Oncotarget; 2017 Aug; 8(35):59476-59491. PubMed ID: 28938651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction between cyclin T1 and SCF(SKP2) targets CDK9 for ubiquitination and degradation by the proteasome.
    Kiernan RE; Emiliani S; Nakayama K; Castro A; Labbé JC; Lorca T; Nakayama Ki K; Benkirane M
    Mol Cell Biol; 2001 Dec; 21(23):7956-70. PubMed ID: 11689688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cyclin-dependent kinase 9 forms a complex with GATA4 and is involved in the differentiation of mouse ES cells into cardiomyocytes.
    Kaichi S; Takaya T; Morimoto T; Sunagawa Y; Kawamura T; Ono K; Shimatsu A; Baba S; Heike T; Nakahata T; Hasegawa K
    J Cell Physiol; 2011 Jan; 226(1):248-54. PubMed ID: 20665673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia.
    Cheng W; Li S; Wen X; Han S; Wang S; Wei H; Song Z; Wang Y; Tian X; Zhang X
    Chem Commun (Camb); 2021 Nov; 57(95):12852-12855. PubMed ID: 34788776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Site-specific regulation of histone H1 phosphorylation in pluripotent cell differentiation.
    Liao R; Mizzen CA
    Epigenetics Chromatin; 2017; 10():29. PubMed ID: 28539972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-loop phosphorylated Cdk9 localizes to nuclear speckle domains which may serve as sites of active P-TEFb function and exchange between the Brd4 and 7SK/HEXIM1 regulatory complexes.
    Dow EC; Liu H; Rice AP
    J Cell Physiol; 2010 Jul; 224(1):84-93. PubMed ID: 20201073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism.
    Lu H; Xue Y; Yu GK; Arias C; Lin J; Fong S; Faure M; Weisburd B; Ji X; Mercier A; Sutton J; Luo K; Gao Z; Zhou Q
    Elife; 2015 Jun; 4():e06535. PubMed ID: 26083714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential localization and expression of the Cdk9 42k and 55k isoforms.
    Liu H; Herrmann CH
    J Cell Physiol; 2005 Apr; 203(1):251-60. PubMed ID: 15452830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Establishment of a Hyperactive Structure Allows the Tumour Suppressor Protein p53 to Function through P-TEFb during Limited CDK9 Kinase Inhibition.
    Albert TK; Antrecht C; Kremmer E; Meisterernst M
    PLoS One; 2016; 11(1):e0146648. PubMed ID: 26745862
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology.
    Wang S; Fischer PM
    Trends Pharmacol Sci; 2008 Jun; 29(6):302-13. PubMed ID: 18423896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
    Cai D; Byth KF; Shapiro GI
    Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting CDK9: a promising therapeutic opportunity in prostate cancer.
    Rahaman MH; Kumarasiri M; Mekonnen LB; Yu M; Diab S; Albrecht H; Milne RW; Wang S
    Endocr Relat Cancer; 2016 Dec; 23(12):T211-T226. PubMed ID: 27582311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation.
    Ivanov D; Kwak YT; Nee E; Guo J; García-Martínez LF; Gaynor RB
    J Mol Biol; 1999 Apr; 288(1):41-56. PubMed ID: 10329125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging picture of CDK9/P-TEFb: more than 20 years of advances since PITALRE.
    Paparidis NF; Durvale MC; Canduri F
    Mol Biosyst; 2017 Jan; 13(2):246-276. PubMed ID: 27833949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.
    Tong Y; Florjancic AS; Clark RF; Lai C; Mastracchio A; Zhu GD; Smith ML; Kovar PJ; Shaw B; Albert DH; Qiu W; Longenecker KL; Liu X; Olson AM; Osterling DJ; Tahir SK; Phillips DC; Leverson JD; Souers AJ; Penning TD
    ACS Med Chem Lett; 2021 Jul; 12(7):1108-1115. PubMed ID: 34267880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.